{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:03:49Z","timestamp":1771542229805,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of Ras-related dexamethasone-induced 1 (RASD1) in multiple myeloma (MM) pathogenesis remains unclear. This study investigated the expression profile, clinical significance, and epigenetic regulation of RASD1 in MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bone marrow samples were collected from 26 newly diagnosed patients with MM and 8 healthy controls. RASD1 messenger RNA (mRNA) and protein expression were analyzed using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry, respectively. DNA methylation status was assessed via methylation-specific PCR (MSP). The U266 MM cell line was treated with the demethylating agent decitabine (DAC) to evaluate its effects on RASD1 expression and apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RASD1 mRNA and protein expression were significantly downregulated in patients with MM compared to healthy controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Low RASD1 mRNA levels correlated significantly with advanced DS stage, anemia, hypercalcemia, and elevated M-protein concentrations (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The receiver operating characteristic curve indicated that RASD1 mRNA expression was a robust discriminator between patients with MM and healthy individuals (area under the curve\u2009=\u20090.882, sensitivity\u2009=\u2009100%, specificity\u2009=\u200975%). MSP analysis revealed RASD1 promoter hypermethylation in patients with MM, whereas controls exhibited hypomethylation. Treatment of U266 cells with DAC restored RASD1 expression and significantly increased apoptosis compared with controls (12.08% vs. 5.04%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RASD1 is frequently silenced in MM through promoter hypermethylation. This epigenetic inactivation is associated with adverse clinical features and enhanced cell survival, supporting a tumor suppressor role for RASD1 in MM pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-026-00125-6","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:35:22Z","timestamp":1770028522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypermethylation-mediated silencing of RASD1 drives multiple myeloma pathogenesis"],"prefix":"10.1007","volume":"61","author":[{"given":"Chenfeng","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghuai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"7","key":"125_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"125_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol"},{"issue":"34","key":"125_CR3","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1038\/sj.onc.1207774","volume":"23","author":"G Vaidyanathan","year":"2004","unstructured":"Vaidyanathan G, Cismowski MJ, Wang G, et al. The Ras-related protein AGS1\/RASD1 suppresses cell growth. Oncogene. 2004;23(34):5858\u201363.","journal-title":"Oncogene"},{"issue":"8","key":"125_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-0033-1341510","volume":"45","author":"J Tian","year":"2013","unstructured":"Tian J, Duan YX, Bei CY, et al. Calycosin induces apoptosis by upregulation of RASD1 in human breast cancer cells MCF-7. Horm Metab Res. 2013;45(8):593\u20138.","journal-title":"Horm Metab Res"},{"issue":"1","key":"125_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000451046","volume":"150","author":"J Both","year":"2016","unstructured":"Both J, Wu T, Ten Asbroek ALMA, et al. Oncogenic properties of candidate oncogenes in chromosome region 17p11.2p12 in human osteosarcoma. Cytogenet Genome Res. 2016;150(1):52\u20139.","journal-title":"Cytogenet Genome Res"},{"issue":"5","key":"125_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/intimm\/dxm023","volume":"19","author":"JW Lindsey","year":"2007","unstructured":"Lindsey JW. Dexamethasone-induced Ras-related protein 1 is a potential regulatory protein in B lymphocytes. Int Immunol. 2007;19(5):583\u201390.","journal-title":"Int Immunol"},{"key":"125_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2019.03.005","volume":"80","author":"S Wang","year":"2019","unstructured":"Wang S, Wang C, Wang W, et al. High RASD1 transcript levels at diagnosis predicted poor survival in adult B-cell acute lymphoblastic leukemia patients. Leuk Res. 2019;80:26\u201332.","journal-title":"Leuk Res"},{"issue":"13","key":"125_CR8","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-08-3336","volume":"15","author":"M Nojima","year":"2009","unstructured":"Nojima M, Maruyama R, Yasui H. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res. 2009;15(13):4356\u201364.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"125_CR9","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"4","key":"125_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^(-\u0394\u0394CT) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"1","key":"125_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1369\/jhc.2010.957191","volume":"59","author":"SR Shi","year":"2011","unstructured":"Shi SR, Shi Y, Taylor CR. Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem. 2011;59(1):13\u201332.","journal-title":"J Histochem Cytochem"},{"key":"125_CR12","first-page":"2597","volume":"50","author":"AM Rieger","year":"2011","unstructured":"Rieger AM, Nelson KL, Konowalchuk JD, et al. Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp. 2011;50:2597.","journal-title":"J Vis Exp"},{"issue":"3","key":"125_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309\u201322.","journal-title":"Ann Oncol"},{"key":"125_CR14","doi-asserted-by":"crossref","unstructured":"Agirre X, Castellano G, Pascual M, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 2015;25(4):478-87.","DOI":"10.1101\/gr.180240.114"},{"key":"125_CR15","doi-asserted-by":"crossref","unstructured":"Garcia-Gomez A, Li T, de la Calle-Fabregat C, et al. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Nat Commun. 2021;12(1):421.","DOI":"10.1038\/s41467-020-20715-x"},{"key":"125_CR16","doi-asserted-by":"crossref","unstructured":"Nojima M, Maruyama R, Yasui H, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res. 2009;15(13):4356-64.","DOI":"10.1158\/1078-0432.CCR-08-3336"},{"key":"125_CR17","doi-asserted-by":"crossref","unstructured":"Ren M, Pan H, Zhou X, et al.\u00a0KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner. J Transl Med. 2024;22(1):584.","DOI":"10.1186\/s12967-024-05375-5"},{"issue":"14","key":"125_CR18","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","volume":"27","author":"CJ Heuck","year":"2021","unstructured":"Heuck CJ. DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in multiple myeloma. Clin Cancer Res. 2021;27(14):3896\u2013907.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"125_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"15","key":"125_CR20","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"8","key":"125_CR21","first-page":"832","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. J Clin Oncol. 2022;40(8):832\u201345.","journal-title":"J Clin Oncol"},{"key":"125_CR22","doi-asserted-by":"crossref","unstructured":"Tirier SM, Mallm JP, Steiger S, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960.","DOI":"10.1038\/s41467-021-26951-z"},{"key":"125_CR23","doi-asserted-by":"crossref","unstructured":"Kumar S, Kats LM, Gruber E. Epigenetic reprogramming in multiple myeloma-Challenges and opportunities. Int J Cancer. 2026;158(2):423-432.","DOI":"10.1002\/ijc.35426"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00125-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:04:29Z","timestamp":1771538669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00125-6","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients and healthy controls provided written informed consent. The study was approved by the Ethics Committee of the Affiliated Hospital of Zunyi Medical University (KLLY-2019-209).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}